RxDoctor Payments Data

Biju Marath, MD

Nephrology · Gulfport, MSNPI 1629234463

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.

$3,090in general payments, 2019–2025

Across 155 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$369
  • Mallinckrodt Hospital Products Inc.$361
  • Amgen$325
  • OPKO Pharmaceuticals, LLC$299
  • AstraZeneca$280
  • Fresenius USA Marketing, Inc.$230
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,00197%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,090 in reported general payments places this provider in the 65th percentile of 105 nephrology providers in Mississippi.

See all nephrology providers in Mississippi

Medicare billing

Part B allowed, 2024
$282,734
Medicare patients
378
Services billed
1,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide18$63,265
RayaldeeCalcifediol46$55,690
VeltassaPatiromer Calcium Sorbitex12$15,596
FarxigaDapagliflozin Propanediol27$15,415
Lanthanum Carbonate11$13,944
Sevelamer Carbonate70$11,559
Cinacalcet Hcl14$3,188
Calcium Acetate18$1,379
Calcitriol83$1,079
Hydralazine Hcl75$881
Losartan Potassium60$478
Potassium Chloride14$356
Midodrine Hcl11$273
Lactulose21$258
Amlodipine Besylate60$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$230$63,26518 claims
OPKO Pharmaceuticals, LLCRayaldee$299$55,69046 claims
AstraZenecaFarxiga$280$15,41527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 105 nephrology providers in Mississippi.

Other nephrology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →